Septran Complications and Contraindications in Pediatrics

Absolute Contraindications

The American Academy of Pediatrics recommends that Septran is absolutely contraindicated in infants younger than 2 months of age due to the risk of kernicterus 1
Septran is contraindicated in patients with known hypersensitivity to trimethoprim or sulfonamides, due to the risk of severe hypersensitivity reactions 1
The American Academy of Dermatology states that Septran is contraindicated in patients with a prior history of immune thrombocytopenia with trimethoprim or sulfonamides 1
Septran is contraindicated in patients with documented folate deficiency-related megaloblastic anemia, as it may worsen the condition 1
The American Academy of Dermatology recommends that Septran is contraindicated in patients with severe hepatic or renal impairment, as it may exacerbate the condition 1

The American Academy of Dermatology reports that Stevens-Johnson syndrome and toxic epidermal necrolysis are life-threatening skin reactions that can be fatal, with a risk associated with Septran use 1, 2
Erythema multiforme and exfoliative dermatitis are severe hypersensitivity skin manifestations that can occur with Septran use 1, 2
Agranulocytosis and aplastic anemia are potentially fatal bone marrow suppression complications that can occur with Septran use 1, 2
Thrombocytopenia, including thrombotic thrombocytopenic purpura and idiopathic thrombocytopenic purpura, can occur with Septran use 1, 2
Hemolytic anemia, leukopenia, neutropenia, and megaloblastic anemia are various blood dyscrasias that can occur with Septran use 1, 2
Fulminant hepatic necrosis is a fatal liver failure complication that has been reported with Septran use 1, 2
Hepatitis with cholestatic jaundice can occur with Septran use, characterized by elevation of transaminases and bilirubin 1, 2

Nausea, vomiting, diarrhea, abdominal pain, and anorexia are common gastrointestinal adverse effects of Septran 1, 2
Pseudomembranous enterocolitis, including Clostridium difficile-associated diarrhea, can occur with Septran use 1, 2
Interstitial nephritis and renal failure can occur with Septran use, and may progress to toxic nephrosis with oliguria and anuria 1, 2
Crystalluria can occur with Septran use, and adequate fluid intake must be maintained to prevent crystal formation and renal stones 4
Aseptic meningitis is a rare but serious CNS complication that can occur with Septran use 1, 2
Hyperkalemia is a potentially concerning complication, particularly in patients with renal insufficiency or those on ACE inhibitors 1, 2
Anaphylaxis and anaphylactoid reactions can occur with Septran use 1, 2
Serum sickness-like syndrome and Henoch-Schönlein purpura can occur with Septran use 1, 2

The Centers for Disease Control and Prevention recommends that Septran be used with extreme caution in patients with hepatic impairment, when monitoring is possible 4
Dose adjustment is required when creatinine clearance is <30 mL/min, to prevent accumulation of the drug 4
Folate deficiency states require careful consideration when using Septran, as it may worsen the condition 4
The American Academy of Dermatology states that methotrexate, oral anticoagulants, oral hypoglycemic agents, phenytoin, and cyclosporine may interact with Septran, requiring careful monitoring or dose adjustments 1, 2, 4

Complete blood counts should be monitored periodically to detect hematologic toxicity early 3
Renal function should be monitored, especially in patients with pre-existing renal impairment, by measuring BUN and creatinine 2
Hepatic function should be monitored by measuring transaminases and bilirubin 2
Serum potassium should be monitored, particularly in patients with risk factors for hyperkalemia 2
Adequate hydration should be ensured to prevent crystalluria 4

The American Academy of Pediatrics recommends that children ≥2 months receive standard dosing of 8-12 mg/kg/day (based on trimethoprim component) divided into 2-4 doses 5, 6
Infants 3-24 months may require higher doses for certain infections 6
The Centers for Disease Control and Prevention recommends that Septran not be used in neonates or infants <2 months due to kernicterus risk 1, 4
Septran should be avoided in children with fragile X chromosome due to folate depletion worsening psychomotor regression 1
The American Academy of Dermatology states that Septran should not be used as monotherapy for acne; combination therapy is required 1, 2

The Centers for Disease Control and Prevention recommends that Septran be used as the drug of choice for Pneumocystis jiroveci pneumonia at 15-20 mg/kg/day (TMP component) for 21 days 6
Septran is an alternative agent for pertussis when macrolides are contraindicated in children >2 months 4
The Infectious Diseases Society of America recommends that Septran be used as an alternative for MRSA when other agents are unsuitable 5, 3
The American Academy of Pediatrics states that the benefit-to-risk ratio must be carefully assessed for each patient, with particular attention to age, renal and hepatic function, concurrent medications, and duration of therapy required 3